Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could Legume-Enriched bread help tame blood sugar?

NCT ID NCT07652320

Disease control Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether replacing some wheat flour with legume flours (chickpea, pea, or lentil) in Arabic bread can reduce blood sugar spikes after eating. Overweight or obese adults aged 18–65 will consume different breads and have their blood glucose and appetite measured. The goal is to see if these alternative flours offer a healthier option for blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
legume-enriched bread (chickpea, pea, or lentil flour blend)
What this could lead to
If legume-enriched bread lowers blood sugar spikes, it could offer a simple dietary swap to help manage glucose levels and reduce diabetes risk.
What could go wrong
This is a small, early-stage trial with only 14 participants, so results may not apply broadly. The breads may not taste acceptable or show meaningful differences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants will be adults living with overweight or obesity (Body Mass Index \[BMI\] \> 25 kg/m²). * Participants will be of any gender. * Participants will be aged 18 to 65. * Participants will be from any sociodemographic background. * Participants will be able to provide informed consent. * Participants will be able to understand spoken and written English and be able to record their responses to questionnaires. Exclusion Criteria: * Those with food allergies or intolerances to any of the study ingredients, including wheat, chickpeas, lentils, or peas, will not be eligible. * Individuals with a known diagnosis of metabolic or chronic health conditions, such as diabetes, insulin resistance, hypertension, or phenylketonuria, will be excluded due to the potential impact on glycaemic control and study outcomes. * Participants with a fasting blood glucose level of above 7.0 mmol/L. * Use of medications that influence blood glucose levels (e.g., corticosteroids, antipsychotics, antiviral protease inhibitors) or substances that interfere with digestion and absorption (such as laxatives or fibre supplements) will result in exclusion. * Pregnant or breastfeeding individuals will not be included due to the physiological changes that may influence study outcomes. * Participants with implanted medical devices, including pacemakers, artificial organs, defibrillators, or joint replacements, will be excluded for safety considerations. * Anyone who has undergone major surgery or hospitalisation within the last 5 months will be deemed ineligible. * Individuals who have participated in another research study involving invasive procedures within the last 3 months will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glycaemic response are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glycaemic response Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • School of Biosciences, University of Nottingham, Sutton Bonington Campus, United Kingdom

    Nottingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.